JP6942465B2 - 抗ｐｄｌ１抗体製剤 - Google Patents

抗ｐｄｌ１抗体製剤 Download PDF

Info

Publication number
JP6942465B2
JP6942465B2 JP2016517363A JP2016517363A JP6942465B2 JP 6942465 B2 JP6942465 B2 JP 6942465B2 JP 2016517363 A JP2016517363 A JP 2016517363A JP 2016517363 A JP2016517363 A JP 2016517363A JP 6942465 B2 JP6942465 B2 JP 6942465B2
Authority
JP
Japan
Prior art keywords
antibody
formulation
sequence
antibodies
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016517363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533335A5 (cg-RX-API-DMAC7.html
JP2016533335A (ja
Inventor
イン ヤン，
イン ヤン，
スリードハラ アラバタム，
スリードハラ アラバタム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51703416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6942465(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2016533335A publication Critical patent/JP2016533335A/ja
Publication of JP2016533335A5 publication Critical patent/JP2016533335A5/ja
Priority to JP2021107154A priority Critical patent/JP2021169458A/ja
Application granted granted Critical
Publication of JP6942465B2 publication Critical patent/JP6942465B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016517363A 2013-09-27 2014-09-26 抗ｐｄｌ１抗体製剤 Active JP6942465B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021107154A JP2021169458A (ja) 2013-09-27 2021-06-29 抗ｐｄｌ１抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361883953P 2013-09-27 2013-09-27
US61/883,953 2013-09-27
PCT/US2014/057821 WO2015048520A1 (en) 2013-09-27 2014-09-26 Anti-pdl1 antibody formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019104978A Division JP2019194195A (ja) 2013-09-27 2019-06-05 抗ｐｄｌ１抗体製剤
JP2021107154A Division JP2021169458A (ja) 2013-09-27 2021-06-29 抗ｐｄｌ１抗体製剤

Publications (3)

Publication Number Publication Date
JP2016533335A JP2016533335A (ja) 2016-10-27
JP2016533335A5 JP2016533335A5 (cg-RX-API-DMAC7.html) 2017-11-09
JP6942465B2 true JP6942465B2 (ja) 2021-09-29

Family

ID=51703416

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016517363A Active JP6942465B2 (ja) 2013-09-27 2014-09-26 抗ｐｄｌ１抗体製剤
JP2019104978A Withdrawn JP2019194195A (ja) 2013-09-27 2019-06-05 抗ｐｄｌ１抗体製剤
JP2021107154A Withdrawn JP2021169458A (ja) 2013-09-27 2021-06-29 抗ｐｄｌ１抗体製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019104978A Withdrawn JP2019194195A (ja) 2013-09-27 2019-06-05 抗ｐｄｌ１抗体製剤
JP2021107154A Withdrawn JP2021169458A (ja) 2013-09-27 2021-06-29 抗ｐｄｌ１抗体製剤

Country Status (32)

Country Link
US (4) US10875922B2 (cg-RX-API-DMAC7.html)
EP (3) EP4285928A3 (cg-RX-API-DMAC7.html)
JP (3) JP6942465B2 (cg-RX-API-DMAC7.html)
KR (1) KR102331663B1 (cg-RX-API-DMAC7.html)
CN (1) CN105793288B (cg-RX-API-DMAC7.html)
AR (2) AR097791A1 (cg-RX-API-DMAC7.html)
AU (3) AU2014324703C1 (cg-RX-API-DMAC7.html)
BR (1) BR112016006397B1 (cg-RX-API-DMAC7.html)
CA (1) CA2925310C (cg-RX-API-DMAC7.html)
CL (1) CL2016000680A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160141A (cg-RX-API-DMAC7.html)
DK (1) DK3049441T3 (cg-RX-API-DMAC7.html)
EA (2) EA033817B1 (cg-RX-API-DMAC7.html)
ES (1) ES2768614T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200102T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047194T2 (cg-RX-API-DMAC7.html)
IL (3) IL244712B (cg-RX-API-DMAC7.html)
LT (1) LT3049441T (cg-RX-API-DMAC7.html)
MA (1) MA38960A1 (cg-RX-API-DMAC7.html)
MX (3) MX375378B (cg-RX-API-DMAC7.html)
MY (1) MY175472A (cg-RX-API-DMAC7.html)
NZ (1) NZ719036A (cg-RX-API-DMAC7.html)
PE (1) PE20160541A1 (cg-RX-API-DMAC7.html)
PH (2) PH12016500566A1 (cg-RX-API-DMAC7.html)
PL (1) PL3049441T3 (cg-RX-API-DMAC7.html)
PT (1) PT3049441T (cg-RX-API-DMAC7.html)
RS (1) RS59880B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201708542RA (cg-RX-API-DMAC7.html)
SI (1) SI3049441T1 (cg-RX-API-DMAC7.html)
TW (2) TWI660738B (cg-RX-API-DMAC7.html)
UA (1) UA122478C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015048520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP4285928A3 (en) 2013-09-27 2024-03-13 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
AU2015274408A1 (en) 2014-06-13 2017-01-12 Mayo Foundation For Medical Education And Research Treating lymphomas
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
CA3025145A1 (en) * 2015-05-22 2016-12-01 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
CN108289953B (zh) 2015-09-29 2022-03-11 细胞基因公司 Pd-1结合蛋白及其使用方法
EP3356551B1 (en) 2015-09-29 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of b-lymphomas
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CA3004804A1 (en) 2015-11-17 2017-05-26 Jiangsu Hengrui Medicine Co., Ltd. Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof
BR112018010211A2 (pt) 2015-12-07 2019-02-05 Merck Patent Gmbh formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
PT3394103T (pt) 2015-12-22 2023-09-04 Regeneron Pharma Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro
EP3400443B1 (en) 2016-01-04 2020-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
CA3014531A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CN109153719B (zh) 2016-03-15 2022-12-30 中外制药株式会社 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
US10077308B2 (en) 2016-06-13 2018-09-18 Askgene Pharma Inc. PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
CN115998859A (zh) 2016-06-27 2023-04-25 莫佛塞斯公司 抗-cd19抗体制剂
WO2018027524A1 (en) * 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
KR20190125363A (ko) * 2017-03-06 2019-11-06 메르크 파텐트 게엠베하 수성 항-pd-l1 항체 제제
US20210186982A1 (en) 2017-03-24 2021-06-24 Universite Nice Sophia Antipolis Methods and compositions for treating melanoma
MX2019010999A (es) * 2017-03-29 2020-02-05 Celgene Corp Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas.
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
JP7263256B6 (ja) * 2017-05-16 2023-07-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｐｄ－ｌ１抗体医薬組成物およびその使用
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
CN107384870A (zh) * 2017-07-31 2017-11-24 时力生物科技（北京）有限公司 一种靶向pd‑l1嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用
WO2019032663A1 (en) * 2017-08-09 2019-02-14 Orionis Biosciences Inc. PD-1 AND PD-L1 BINDING AGENTS
US20200216542A1 (en) * 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
CN114632150B (zh) * 2017-11-02 2023-12-19 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
EP3735590A1 (en) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
CA3087105A1 (en) 2018-01-10 2019-07-18 Jiangsu Hengrui Medicine Co., Ltd. Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP3756012A1 (en) 2018-02-21 2020-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
US12331068B2 (en) 2018-05-31 2025-06-17 Peloton Therapeutics, Inc. Compositions and methods for inhibiting CD73
KR20210056288A (ko) * 2018-06-01 2021-05-18 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 질환 또는 병태를 치료하기 위한 조성물 및 그의 용도
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
WO2020007817A1 (en) * 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
CN112955221A (zh) 2018-08-27 2021-06-11 皮里斯制药有限公司 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
WO2020094744A1 (en) * 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
EP3883964A1 (en) 2018-11-20 2021-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2020108497A1 (zh) * 2018-11-29 2020-06-04 和铂医药（香港）有限公司 一种抗pd-l1抗体制剂
TW202034951A (zh) 2018-12-07 2020-10-01 日商小野藥品工業股份有限公司 免疫抑制劑
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
MA54448A (fr) 2018-12-11 2021-10-20 Theravance Biopharma R&D Ip Llc Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
JP7442536B2 (ja) 2019-01-30 2024-03-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンを患っている被験体が免疫チェックポイント阻害剤で反応を達成するかを特定するための方法及び組成物
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN109929037B (zh) 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
EP3963109A1 (en) 2019-04-30 2022-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
KR20220034169A (ko) * 2019-07-10 2022-03-17 리제너론 파아마슈티컬스, 인크. 감소된 수준의 숙주 세포 단백질을 포함하는 방법 및 조성물
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US20220354811A1 (en) 2019-10-03 2022-11-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
CA3157889A1 (en) 2019-10-17 2021-04-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for diagnosing nasal intestinal type adenocarcinomas
JP7450710B2 (ja) 2019-10-21 2024-03-15 上▲海▼宏成▲薬▼▲業▼有限公司 抗ｐｄ－ｌ１抗体及びその製薬用途
US20240122938A1 (en) 2019-10-29 2024-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
CA3160307A1 (en) 2019-11-22 2021-05-27 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
AU2020399619A1 (en) * 2019-12-09 2022-06-09 Genentech, Inc. Anti-PD-L1 antibody formulations
WO2021123243A1 (en) 2019-12-19 2021-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
EP4090770A1 (en) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US20230072528A1 (en) 2020-02-05 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
EP4110955A1 (en) 2020-02-28 2023-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2021203131A1 (en) 2020-03-31 2021-10-07 Theravance Biopharma R&D Ip, Llc Substituted pyrimidines and methods of use
TW202214623A (zh) 2020-06-10 2022-04-16 美商施萬生物製藥研發 Ip有限責任公司 結晶型alk5抑制劑及其用途
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
EP4244392A1 (en) 2020-11-16 2023-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for predicting and treating uveal melanoma
US20230416830A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022194908A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
JP2024544358A (ja) * 2021-10-29 2024-11-29 ナセント バイオテック インコーポレイテッド ビメンチンを発現する腫瘍を治療するためのキットおよび容器
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
KR20240111310A (ko) * 2021-12-08 2024-07-16 훼링 비.브이. 단백질 정제 방법
US20250041261A1 (en) 2021-12-21 2025-02-06 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024126750A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024231384A1 (en) 2023-05-10 2024-11-14 Institut National de la Santé et de la Recherche Médicale Compositions for treating senescence related disease
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025132770A1 (en) 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025219330A1 (en) 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2332893T3 (es) 1996-08-30 2010-02-15 Upfront Chromatography A/S Aislamiento de inmunoglobulinas.
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
AU2002243228B2 (en) * 2000-11-16 2007-08-02 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery
CA2447114A1 (en) 2001-05-16 2002-11-21 Abgenix, Inc. Human antipneumococcal antibodies from non-human animals
DK1425389T3 (da) 2001-08-23 2012-01-30 Genmab As Interleukin-15-(IL-15)-specifikke humane antistoffer
CN1761482A (zh) 2003-01-17 2006-04-19 纽约州立大学研究基金会 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004270103B2 (en) 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
AU2011274363A1 (en) * 2010-07-02 2013-01-24 Medimmune, Llc Antibody formulations
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
TWI835048B (zh) * 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
MX349096B (es) * 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
CA3111357A1 (en) * 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
BR112015028326A8 (pt) 2013-06-03 2018-01-23 Novartis Ag combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
EP4285928A3 (en) 2013-09-27 2024-03-13 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體

Also Published As

Publication number Publication date
TW201542225A (zh) 2015-11-16
IL244712A0 (en) 2016-04-21
AU2014324703C1 (en) 2020-10-29
AU2022235627A1 (en) 2022-12-22
IL285474A (en) 2021-09-30
PH12016500566A1 (en) 2016-05-23
HRP20200102T1 (hr) 2020-04-03
US20160319022A1 (en) 2016-11-03
MA38960A1 (fr) 2017-10-31
EP3626742A1 (en) 2020-03-25
CA2925310A1 (en) 2015-04-02
EA033817B1 (ru) 2019-11-28
KR102331663B1 (ko) 2021-11-25
AU2014324703B2 (en) 2020-03-19
IL270165B (en) 2021-08-31
LT3049441T (lt) 2020-02-10
AU2020203267B2 (en) 2022-06-23
CL2016000680A1 (es) 2016-12-23
JP2019194195A (ja) 2019-11-07
CN105793288B (zh) 2020-03-03
US20250145717A1 (en) 2025-05-08
PH12019501931A1 (en) 2020-06-15
SG11201602283UA (en) 2016-04-28
AR130402A2 (es) 2024-12-04
MY175472A (en) 2020-06-29
MX2022014781A (es) 2023-01-16
DK3049441T3 (da) 2020-02-03
UA122478C2 (uk) 2020-11-25
TW201936209A (zh) 2019-09-16
EP3049441B1 (en) 2019-11-27
IL244712B (en) 2020-02-27
US20210221892A1 (en) 2021-07-22
BR112016006397B1 (pt) 2024-01-16
PL3049441T3 (pl) 2020-04-30
EP4285928A2 (en) 2023-12-06
EP3049441A1 (en) 2016-08-03
SG10201708542RA (en) 2017-12-28
HK1222867A1 (zh) 2017-07-14
MX375378B (es) 2025-03-06
US10875922B2 (en) 2020-12-29
RS59880B1 (sr) 2020-03-31
AU2020203267A1 (en) 2020-06-11
WO2015048520A1 (en) 2015-04-02
EA201991715A1 (ru) 2020-03-31
JP2016533335A (ja) 2016-10-27
EA201690667A1 (ru) 2016-08-31
EP4285928A3 (en) 2024-03-13
ES2768614T3 (es) 2020-06-23
PE20160541A1 (es) 2016-06-03
KR20160058938A (ko) 2016-05-25
PT3049441T (pt) 2020-01-21
CN105793288A (zh) 2016-07-20
CA2925310C (en) 2022-12-06
JP2021169458A (ja) 2021-10-28
HUE047194T2 (hu) 2020-04-28
TWI714022B (zh) 2020-12-21
AU2014324703A1 (en) 2016-04-21
TWI660738B (zh) 2019-06-01
MX2020010026A (es) 2020-10-14
MX2016003939A (es) 2016-06-17
US20240010732A1 (en) 2024-01-11
CR20160141A (es) 2016-07-15
AR097791A1 (es) 2016-04-13
NZ719036A (en) 2022-02-25
SI3049441T1 (sl) 2020-03-31
BR112016006397A2 (pt) 2017-09-26

Similar Documents

Publication Publication Date Title
JP6942465B2 (ja) 抗ｐｄｌ１抗体製剤
JP6814962B2 (ja) 抗体製剤
CN102770158B (zh) 抗体配制剂
CN106794247B (zh) 抗体配制剂
JP2012519706A (ja) 抗体製剤
ES3038408T3 (en) Formulations with reduced degradation of polysorbate
CN108430455A (zh) 色氨酸衍生物用于蛋白质配制剂的用途
US20250388677A1 (en) Anti-pdl1 antibody formulations
HK1222867B (zh) 抗pdl1抗体配制剂
HK40018326A (en) Antibody formulations
HK1238532B (en) Antibody formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190605

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190605

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190614

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190618

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190705

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190709

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200602

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200923

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210330

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20210401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210706

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210713

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210817

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210908

R150 Certificate of patent or registration of utility model

Ref document number: 6942465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250